EMA: Reflection paper on Immune Tolerance Induction in haemophilia A patients with inhibitors

In haemophilia A patients, replacement therapy with factor VIII products has become state of the art. However, a serious complication in the treatment of haemophilia A is the development of neutralizing antibodies against FVIII, causing therapy resistance and increased risk of bleeding.